- Home
- DIAX vs CATX Comparison
DIAX vs CATX Comparison
Compare DIAX & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$3.66
Company Overview
Basic Information| Metric | DIAX | CATX |
|---|---|---|
| Founded | 2005 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 525.1M | 497.9M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | DIAX | CATX |
|---|---|---|
| Price | $14.10 | $3.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $12.11 |
| AVG Volume (30 Days) | 100.4K | ★ 1.5M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 7.93% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.63 | $1.96 |
| 52 Week High | $15.85 | $6.16 |
Technical Indicators
Market Signals| Indicator | DIAX | CATX |
|---|---|---|
| Relative Strength Index (RSI) | 30.87 | 39.31 |
| Support Level | $13.73 | $3.52 |
| Resistance Level | $14.45 | $3.80 |
| Average True Range (ATR) | 0.21 | 0.27 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 10.26 | 22.79 |
Price Performance
Historical Comparison DIAX
CATX
About DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest
Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the S&P 500 Index.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.